August 7, 2017
GCA Altium advises Micro-Macinazione on its sale to Lonza
GCA Altium acted as exclusive financial advisor to Cross, the majority shareholders of Micro-Macinazione, on the sale to Lonza, the Swiss listed CDMO.
Micro-Macinazione is the leading independent global player in the micronization market, offering top-class micronization services, manufacturing of micronization equipment and R&D capabilities for the pharmaceutical industry.
The acquisition of Micro-Macinazione creates a global leader in the field of micronization services by building on Lonza/Capsugel’s existing clinical and commercial manufacturing capabilities in micronization.
Carlo Dawan, Managing Director at GCA Altium, commented: “This transaction marks the latest in a series of successful deals in the pharmaceuticals space for GCA Altium and confirms our strong presence in the Swiss region of Ticino.”
GCA Altium has advised on ten healthcare industry deals in the last year, including the recent sale of Trifarma, a leading manufacturer of active pharmaceutical ingredients. Terms of the transaction were not disclosed.